A Systematic Review and Meta-Analysis of the Diagnostic Value of Galectin-3 in Acute Coronary Syndrome
Journal of Clinical Medicine · 01.08.2024 · 13 (15) · 4504
DOI: 10.3390/jcm13154504 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.08.2024. Verfasst von Michal Pruc und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research and Development, LUX MED Group, 02-678 Warsaw, Poland. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: We investigated the potential diagnostic role of galectin-3 (Gal-3) in patients presenting with suspected acute coronary syndromes (ACS).
Methods
We searched PubMed Central, Scopus, EMBASE, and the Cochrane Library from inception until 20 June 2024. We measured effect sizes using odds ratios (OR) with 95% CIs for dichotomous data and mean differences (MD) with CIs for continuous data. Random synthesis analysis was performed if I2 was less than 50% or Q test p values were less than 0.05. Otherwise, a fixed pooled meta-analysis was performed.
Results
The meta-analysis includes 15 eligible studies. Gal-3 levels were substantially higher in the ACS group (12.84 ± 8.48 ng/mL) compared to the control group (7.23 ± 6.05 ng/mL; MD = 3.89; 95% CI: 2.83 to 4.95; p < 0.001). Gal-3 levels in acute myocardial infarction (AMI) and control groups differed (10.09 ± 8.16 vs. 4.64 ± 3.07 ng/mL, MD = 4.30; 95% CI: 0.41 to 8.18; p < 0.001). Statistical analysis revealed significant differences in Gal-3 levels between ST-elevated myocardial infarction (STEMI) and control groups (10.62 ± 7.34 vs. 5.54 ± 2.96 ng/mL; MD = 5.54; 95% CI: 3.12 to 7.97; p < 0.001). No significant differences were found between the non-ST-elevated myocardial infarction (NSTEMI) vs. control groups or patients with STEMI vs. patients with NSTEMI.
Conclusions
Gal-3 may be beneficial for detecting acute coronary syndromes but not NSTEMI or differentiating between ACS types. This meta-analysis is promising, but further research is needed to prove Gal-3’s potential diagnostic value, exact cut-offs, and advantages over cardiospecific troponins. Gal-3 may be a useful diagnostic biomarker; however, more clinical trials are needed to prove its utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Research and Development, LUX MED Group, 02-678 Warsaw, Poland.
- Department of Public Health, International European University, 03187 Kyiv, Ukraine.
- Department of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, 80-416 Gdansk, Poland.
- Department of Cardiology and Internal Medicine, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland.
- Department of Emergency, Florida State University College of Medicine, Emergency Medicine Residency Program, Sarasota Memorial Hospital, Sarasota, FL 32306, USA.
- Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, 00-136 Warsaw, Poland.
ORCID-Profile: Michal Pruc, Damian Swieczkowski, Jacek Kubica, Sagar Galwankar, Anna Salak
Zitieren
APA
Pruc, M., Gaca, Z., Swieczkowski, D., Kubica, J., Galwankar, S., Salak, A., & Szarpak, L. (2024). A Systematic Review and Meta-Analysis of the Diagnostic Value of Galectin-3 in Acute Coronary Syndrome. Journal of Clinical Medicine, 13(15), 4504. https://doi.org/10.3390/jcm13154504
Vancouver
Pruc M, Gaca Z, Swieczkowski D, Kubica J, Galwankar S, Salak A, et al. A Systematic Review and Meta-Analysis of the Diagnostic Value of Galectin-3 in Acute Coronary Syndrome. Journal of Clinical Medicine. 2024;13(15):4504. doi:10.3390/jcm13154504
BibTeX
@article{Pruc2024,
author = {Pruc, Michal and Gaca, Zuzanna and Swieczkowski, Damian and Kubica, Jacek and Galwankar, Sagar and Salak, Anna and Szarpak, Lukasz},
title = {A Systematic Review and Meta-Analysis of the Diagnostic Value of Galectin-3 in Acute Coronary Syndrome},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {15},
pages = {4504},
doi = {10.3390/jcm13154504}
}
EUVIMED